11/12/2022 0 Comments Paul argen![]() Below is a recorded conversation on Augof Paul Argen, Chief Compliance Officer with the Mayor of Parsippany NJ, Mayor Michael Soriano, who promised a meeting to discuss why the false and libel press release that was wrongly distributed by the Mayor on Augneeds to be redacted without delay (it incites racism).On August 27, 2021, it was confirmed (by Police Detectives) that AJACO is indeed the victim of alledged crimes by not only the same predator who was on their property and place of business for 6 hours (on August 16, 2021) but the Chief of Police and Mayor of Parsippany are now under an active investigation for alledged crimes and/or alledged wrongdoing for misusing the Public Information Office (amisdt an election nonetheless).Both the Mayor and Chief of Police fail to recognize that on AugAlex Bennet, an assistant prosecutor of Morris County Prosecutor's office had already determined that the circumances show that AJACO Towing or any of its employees or anyone affiliated with AJACO Towing did not demonastrate behavior that met the requirements for a bias incident.The Mayor and Chief of Police then takes away companies Tow Rotation Agreement and voids any future business with AJACO TOWING INC. On Augthe Mayor of Parsippany NJ authorized the release a press release that says that the Town does not condone racism and therefore does not do business with companies that condone racism.Llamas are outbred and therefore have no blind spots in their immune systems. PAUL ARGEN LICENSEThis is the third disclosed license agreement for Potelligent and CHOK1SV, following deals with AstraZeneca in December and Pfizer in July 2013.īioWa has licensed its Potelligent technology to arGEN-X since 2010, and the addition of Lonza’s cell line this week makes this a tripartite agreement.ĪrGEN- X uses llama antibodies for its discovery platform rather than transgenic mice, the industry standard. The result of the collaboration, she said, was an FUT8 double gene knock out variant of CHOK1SV, developed for therapeutic protein expression. “ A cell line with knockout of both alleles for the gene responsible for fucose addition (α1,6-fucosyltransferase FUT8) can take advantage of this phenomenon, producing Potelligent mAbs with enhanced ADCC activity.” “ They confirmed that the mechanism behind the enhanced ADCC of a low/no-fucose antibody was its increased affinity to FcγRIIIa (CD16), the major Fc receptor for ADCC in humans. Ltd (now Kyowa Hakko Kirin) demonstrated that an antibody with a reduced fucose content in glycan moieties exhibited much higher antibody dependent cellular cytotoxicity (ADCC) activity compared to a normally fucosylated antibody,” said Fallen. Under the agreement, this host cell line is used to produce the high-ADCC mAbs created by BioWa’s technology. Its pre-adaptation to suspension culture aids adaptation of GS cell lines back to growth in suspension culture after transfection.” Karen Fallen, VP of Licensing and Technology at Lonza, told Lonza’s host cell line is “ pre-adapted to growth in chemically defined, animal component-free (CDACF) media and suspension culture. It works in three ways: cancer cell depletion via ADCC, and deprivation of both a key stimulation signal and immune privilege. Lonza said the combined technology is “ designed to improve the potency and efficacy of therapeutic antibodies by enhancing antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of therapeutic antibodies.”ĪrGEN-X will use the tech to develop ARGX-110, a monoclonal antibody in its pipeline which targets CD70 positive tumours. Potelligent CHOK1SV cell line is a combination of BioWa’s Potelligent glycosylation technology and Lonza’s GS Gene Expression System, which uses Lonza’s host cell line CHOK1SV. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |